AMNEAL PHARMACEUTICALS INC (AMRX) Fundamental Analysis & Valuation
NASDAQ:AMRX • US03168L1052
Current stock price
13.05 USD
-0.07 (-0.53%)
At close:
13.23 USD
+0.18 (+1.38%)
After Hours:
This AMRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AMRX Profitability Analysis
1.1 Basic Checks
- AMRX had positive earnings in the past year.
- AMRX had a positive operating cash flow in the past year.
- In multiple years AMRX reported negative net income over the last 5 years.
- In the past 5 years AMRX always reported a positive cash flow from operatings.
1.2 Ratios
- The Return On Assets of AMRX (1.96%) is better than 82.20% of its industry peers.
- With an excellent Return On Invested Capital value of 11.24%, AMRX belongs to the best of the industry, outperforming 90.58% of the companies in the same industry.
- AMRX had an Average Return On Invested Capital over the past 3 years of 10.04%. This is below the industry average of 13.10%.
- The 3 year average ROIC (10.04%) for AMRX is below the current ROIC(11.24%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.96% | ||
| ROE | N/A | ||
| ROIC | 11.24% |
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
1.3 Margins
- The Profit Margin of AMRX (2.39%) is better than 80.63% of its industry peers.
- AMRX's Profit Margin has declined in the last couple of years.
- AMRX has a Operating Margin of 13.18%. This is amongst the best in the industry. AMRX outperforms 85.34% of its industry peers.
- In the last couple of years the Operating Margin of AMRX has grown nicely.
- AMRX has a Gross Margin (36.88%) which is in line with its industry peers.
- AMRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.18% | ||
| PM (TTM) | 2.39% | ||
| GM | 36.88% |
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
2. AMRX Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMRX is still creating some value.
- The number of shares outstanding for AMRX has been increased compared to 1 year ago.
- Compared to 5 years ago, AMRX has more shares outstanding
- AMRX has a better debt/assets ratio than last year.
2.2 Solvency
- AMRX has an Altman-Z score of 1.98. This is not the best score and indicates that AMRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- AMRX has a Altman-Z score of 1.98. This is comparable to the rest of the industry: AMRX outperforms 59.16% of its industry peers.
- AMRX has a debt to FCF ratio of 11.66. This is a negative value and a sign of low solvency as AMRX would need 11.66 years to pay back of all of its debts.
- AMRX has a Debt to FCF ratio of 11.66. This is in the better half of the industry: AMRX outperforms 78.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.66 | ||
| Altman-Z | 1.98 |
ROIC/WACC1.17
WACC9.58%
2.3 Liquidity
- AMRX has a Current Ratio of 2.17. This indicates that AMRX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of AMRX (2.17) is comparable to the rest of the industry.
- AMRX has a Quick Ratio of 1.48. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
- AMRX has a Quick ratio of 1.48. This is in the lower half of the industry: AMRX underperforms 67.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.48 |
3. AMRX Growth Analysis
3.1 Past
- AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.83%, which is quite impressive.
- The Earnings Per Share has been growing slightly by 5.92% on average over the past years.
- AMRX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.05%.
- Measured over the past years, AMRX shows a quite strong growth in Revenue. The Revenue has been growing by 8.66% on average per year.
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%
3.2 Future
- The Earnings Per Share is expected to grow by 5.77% on average over the next years.
- Based on estimates for the next years, AMRX will show a decrease in Revenue. The Revenue will decrease by -0.47% on average per year.
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. AMRX Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 15.54, the valuation of AMRX can be described as correct.
- Based on the Price/Earnings ratio, AMRX is valued cheaper than 85.86% of the companies in the same industry.
- AMRX's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.38.
- With a Price/Forward Earnings ratio of 12.92, AMRX is valued correctly.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 83.77% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 38.20, AMRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.54 | ||
| Fwd PE | 12.92 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 87.43% of the companies in the same industry.
- 85.34% of the companies in the same industry are more expensive than AMRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.45 | ||
| EV/EBITDA | 10.51 |
4.3 Compensation for Growth
- AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of AMRX may justify a higher PE ratio.
- AMRX's earnings are expected to grow with 18.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.77
PEG (5Y)2.62
EPS Next 2Y19.5%
EPS Next 3Y18.59%
5. AMRX Dividend Analysis
5.1 Amount
- AMRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AMRX Fundamentals: All Metrics, Ratios and Statistics
13.05
-0.07 (-0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27 2026-02-27/bmo
Earnings (Next)05-01 2026-05-01
Inst Owners45.62%
Inst Owner Change0.05%
Ins Owners43.95%
Ins Owner Change8.28%
Market Cap4.16B
Revenue(TTM)3.02B
Net Income(TTM)72.06M
Analysts81.82
Price Target16.83 (28.97%)
Short Float %4.33%
Short Ratio3.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.37%
Min EPS beat(2)11.53%
Max EPS beat(2)21.21%
EPS beat(4)4
Avg EPS beat(4)28.29%
Min EPS beat(4)11.53%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)21.12%
EPS beat(12)11
Avg EPS beat(12)30.53%
EPS beat(16)12
Avg EPS beat(16)21.16%
Revenue beat(2)0
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)-0.41%
Revenue beat(4)0
Avg Revenue beat(4)-2.73%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)-0.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.24%
Revenue beat(12)6
Avg Revenue beat(12)0.1%
Revenue beat(16)8
Avg Revenue beat(16)-0.09%
PT rev (1m)13.79%
PT rev (3m)17.86%
EPS NQ rev (1m)0.92%
EPS NQ rev (3m)-14.47%
EPS NY rev (1m)3.53%
EPS NY rev (3m)6.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.81%
Revenue NY rev (1m)-1%
Revenue NY rev (3m)-3.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.54 | ||
| Fwd PE | 12.92 | ||
| P/S | 1.38 | ||
| P/FCF | 18.45 | ||
| P/OCF | 12.24 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.51 |
EPS(TTM)0.84
EY6.44%
EPS(NY)1.01
Fwd EY7.74%
FCF(TTM)0.71
FCFY5.42%
OCF(TTM)1.07
OCFY8.17%
SpS9.46
BVpS-0.22
TBVpS-3.86
PEG (NY)0.77
PEG (5Y)2.62
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.96% | ||
| ROE | N/A | ||
| ROCE | 14.23% | ||
| ROIC | 11.24% | ||
| ROICexc | 12.5% | ||
| ROICexgc | 23.19% | ||
| OM | 13.18% | ||
| PM (TTM) | 2.39% | ||
| GM | 36.88% | ||
| FCFM | 7.47% |
ROA(3y)-1.27%
ROA(5y)-1.39%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)10.04%
ROIC(5y)8.08%
ROICexc(3y)10.72%
ROICexc(5y)8.59%
ROICexgc(3y)22.54%
ROICexgc(5y)18.52%
ROCE(3y)13.13%
ROCE(5y)10.51%
ROICexgc growth 3Y26.84%
ROICexgc growth 5Y18.51%
ROICexc growth 3Y34.73%
ROICexc growth 5Y26.54%
OM growth 3Y13.53%
OM growth 5Y12.51%
PM growth 3YN/A
PM growth 5Y-12.19%
GM growth 3Y0.83%
GM growth 5Y2.08%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 11.66 | ||
| Debt/EBITDA | 4.22 | ||
| Cap/Depr | 51.15% | ||
| Cap/Sales | 3.79% | ||
| Interest Coverage | 2.01 | ||
| Cash Conversion | 54.71% | ||
| Profit Quality | 313.13% | ||
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.48 | ||
| Altman-Z | 1.98 |
F-Score7
WACC9.58%
ROIC/WACC1.17
Cap/Depr(3y)37.69%
Cap/Depr(5y)34.67%
Cap/Sales(3y)3.12%
Cap/Sales(5y)3.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.83%
EPS 3Y7.3%
EPS 5Y5.92%
EPS Q2Q%75%
EPS Next Y20.21%
EPS Next 2Y19.5%
EPS Next 3Y18.59%
EPS Next 5Y5.77%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y10.92%
Revenue growth 5Y8.66%
Sales Q2Q%11.47%
Revenue Next Year2.6%
Revenue Next 2Y4.84%
Revenue Next 3Y5.45%
Revenue Next 5Y-0.47%
EBIT growth 1Y14.22%
EBIT growth 3Y25.92%
EBIT growth 5Y22.25%
EBIT Next Year43.16%
EBIT Next 3Y20.98%
EBIT Next 5Y8.1%
FCF growth 1Y2.51%
FCF growth 3YN/A
FCF growth 5Y-6.32%
OCF growth 1Y15.21%
OCF growth 3Y73.5%
OCF growth 5Y-2.15%
AMNEAL PHARMACEUTICALS INC / AMRX Fundamental Analysis FAQ
What is the fundamental rating for AMRX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AMRX.
What is the valuation status for AMRX stock?
ChartMill assigns a valuation rating of 8 / 10 to AMNEAL PHARMACEUTICALS INC (AMRX). This can be considered as Undervalued.
Can you provide the profitability details for AMNEAL PHARMACEUTICALS INC?
AMNEAL PHARMACEUTICALS INC (AMRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for AMRX stock?
The Price/Earnings (PE) ratio for AMNEAL PHARMACEUTICALS INC (AMRX) is 15.54 and the Price/Book (PB) ratio is -58.8.
Can you provide the expected EPS growth for AMRX stock?
The Earnings per Share (EPS) of AMNEAL PHARMACEUTICALS INC (AMRX) is expected to grow by 20.21% in the next year.